PFE - Day One in licensing pact with MabCare for cancer therapy
2024-06-18 13:13:38 ET
More on Day One Biopharmaceuticals
- Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair
- Day One Biopharmaceuticals announces sale of Priority Review Voucher for $108M
- Day One slips despite Ojemda approval as BofA says label “not a home run”
- Seeking Alpha’s Quant Rating on Day One Biopharmaceuticals
- Historical earnings data for Day One Biopharmaceuticals